ArticleSovremennye tekhnologii v meditsine2021
Technology of Informative Feature Selection for Immunosignature Analysis.
Article in Sovremennye tekhnologii v meditsine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main difficulty in practical work with data obtained via immunosignature analysis is high dimensionality and the presence of a significant number of uninformative or false-informative features due to the specific character of the technology. To ensure practically relevant quality of data analysis and classification, it is necessary to take due account of this specific character. MATERIALS AND
methodsThe study involved the use of two normalized data sets obtained from the public biomedical repository and containing the results of immunosignature analysis.The technology for selecting informative features was proposed within the framework of the study. It consisted of three successive steps: 1) breaking a multiclass task into a series of binary tasks using the "one vs all" strategy; 2) screening of false-informative features is performed for each binary comparison by comparing the values of the median of the sets "one" and "all"; 3) ranking of the remaining features according to their informative value and selection of the most informative ones for each binary comparison.To assess the quality of the proposed technology for informative feature selection, we used the results obtained after application of classification based on the filtered data. Support vector method that proved itself in the problems of high-dimensional data classification was used as a classification model.
resultsEffectiveness of the proposed technology for informative feature selection was determined. This technology allows us to provide high quality of classification while significantly reducing the feature space. The number of features eliminated in the second step is approximately 50% for each data set under consideration, which greatly simplifies subsequent data analysis. After the third step, when the feature space is reduced to 15 features, the quality of classification by the macro-average F1-score metric is assessed as 98.9% for the GSE52581 dataset. For the GSE52581 dataset, with the feature space reduced to 266 features, the quality of classification by the macro-average F1-score metric is 91.3%.
conclusionThe results of the work demonstrate the promising outlook of the proposed technology for informative feature selection as applied to the data of immunosignature analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.